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BACKGROUND: Preoperative nutritional deficiency (ND) has been shown to be a valuable prognostic factor in urologic
malignancies. We aimed to investigate the prognostic value of ND in patients with gastric cancer (GC).METHODS: A
single-center cohort of 1026GCpatientsundergoingcurative resectionbetween2003and2012was categorized toND
and nutritionally replete (NR) groups. Patients with body mass index b18.5 kg/m2, preoperative albumin b35 g/l, or
preoperative weight loss ≥5% of body weight were defined as ND. RESULTS: Of the 1026 patients included in the
study, 585 (57.0%) were categorized as ND. Overall survival (OS) at 5 years was 68.5% for ND patients and 44.0% for
NR patients (P b .001). Multivariate analysis revealed that ND was a significant predictor of OS (hazard ratio: 1.954;
95% confidence interval: 1.552-2.460; P b .001). In stage-stratified analysis, it was still independently associated with
OS in tumor-nodes-metastasis stage II and III (P = .004 and P b .001, respectively). Of note, the prognostic
significance of NDwas still maintained when stratified by age, sex, anemia, and adjuvant chemotherapy (all Ps b .05).
CONCLUSION: Preoperative ND is a novel predictor of outcome in GC, especially in stage II to III GC, and may help
clinicians identify high-risk patients for proactive nutritional interventions.
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Over the past decades, the incidence and mortality rate of gastric
cancer (GC) have been steadily decreased. However, GC is still one of
the most common malignancies nowadays, with a high incidence of
recurrence and metastasis even after curative resection [1,2]. In
China, GC is the second leading cause of cancer death among both
men and women in 2015 [3]. Despite advances in surgical
techniques, the long-term postoperative survival of GC patients is
still poor with the relatively late stage of diagnosis [4].
Inmany cancers, independent prognostic factors are useful for selecting
high-risk patients and tailoring treatment. Currently, pathologic stage and
lymph nodes status, which determine theGCAmerican Joint Committee
on Cancer stages, represent the gold standard for assessing GC prognosis
after radical surgery [5]. However, many other tumor features have also
been validated to play an important role in predicting the postoperative
survival in GC. For example, systemic inflammatory response has been
consistently recognized to confer poorer outcome in patients with variouscancers and become the hot topic for clinicians and researchers [6–8].
Moreover, cancer-associated malnutrition is also increasingly appreciated
to have amajor role [9,10].Malnutrition, defined as a nutritional status in
which there is a deficiency of energy, protein, and other nutrients, can
negatively influence the defensive system in our body and may cause
adverse clinical outcomes [11,12]. However, up to now, no ideal indices
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years, nutritional deficiency (ND), a nutritional-based index, has been
demonstrated as a strong predictor of postoperative outcomes in urologic
malignancies [14,15]. With regard to GC, the clinical significance and
prognostic value of this index remain uncertain.
In the present study, we aimed to investigate the prognostic utility of
preoperative ND, as measured by body mass index (BMI), serum
albumin, and preoperative weight loss, in patients undergoing curative
resection for GC.
Material and Methods
Ethics Statement
The study complied with the standards of the Declaration of
Helsinki and was approved by the Research Ethics Committee at the
Cancer Center of Sun Yat-sen University. Written informed consent
was obtained from each patient.
Study Population
This study reviewed 1026 patients undergoing curative resection for
GC at Cancer Center of Sun Yat-sen University between January 2003
and December 2012. All patients were histologically confirmed asTable 1. General Characteristics of 1026 GC Patients
No. of Patients (%)
Age (y)
b 60 544 (53.0%)
≥ 60 482 (47.0%)
Sex
Female 326 (31.8%)
Male 700 (68.2%)
Tumor size (cm)
b5 583 (56.8%)
≥5 443 (43.2%)
Tumor location
Upper third 411 (40.1%)
Middle third 202 (19.7%)
Lower third 413 (40.3%)
Histological grade
Well differentiated 175 (17.1%)
Poorly differentiated 851 (82.9%)
Anemia
No 737 (71.8%)
Yes 289 (28.2%)
BMI (kg/m2)
b18.5 401 (39.1%)
≥18.5 to b25.0 351 (34.2%)
≥25.0 274 (26.7%)
Serum albumin (g/l)
≥35 941 (91.7%)
b35 85 (8.3%)
Preoperative weight loss
b5% 694 (67.6%)
≥5% to ≤10% 221 (21.5%)
N10% 111 (10.8%)
Nutrition status
NR 441 (43.0%)
ND 585 (57.0%)
CEA
Normal 742 (77.6%)
Elevated 214 (22.4%)
TNM stage
I 177 (17.3%)
II 257 (25.0%)
III 592 (57.7%)
Adjuvant chemotherapy
No 393 (38.3%)
Yes 633 (61.7%)having stage I to III gastric adenocarcinoma, with stage determined
according to the 7th edition of the American Joint Committee on
Cancer tumor-nodes-metastasis (TNM) classification [5]. According to
current guidelines, patients with stage II or stage III GC and no
significant comorbidities precluding chemotherapy use were offered
primarily 5-fluorouracil–based adjuvant chemotherapy after surgery
[16–18]. The exclusion criteria were as follows: 1) no entire set of
clinicopathological and laboratory data, 2) neoadjuvant chemotherapy
or radiotherapy, 3) preoperative nutritional intervention (e.g., albumin)
within 1 month before surgery, and 4) clinical evidence of non–
cancer-related malnutrition.
Data Acquisition
Clinicopathological and outcome data were collected by review of the
medical records. Routine laboratory measurements, including the
serum levels of carcinoembryonic antigen (CEA) and albumin, were
carried out within 1 week before surgery. Unintentional preoperative
weight loss within 6 months was recorded at the time of diagnosis.
Regarding the histological grade, patients with papillary and well- orTable 2. Univariate and Multivariate Analyses of OS in 1026 Patients Undergoing Curative
Resection for GC
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
Age (y) b.001 b.001
b60 1.00 1.00
≥60 1.462 (1.200-1.781) 1.556 (1.259-1.923)
Sex .188
Female 1.00
Male 0.870 (0.707-1.071)
Tumor size (cm) b.001 .705
b5 1.00 1.00
≥5 1.915 (1.571-2.335) 1.044 (0.837-1.302)
Tumor location b.001 .003
Upper third 1.00 1.00
Middle third 0.613 (0.467-0.804) b.001 0.769 (0.578-1.025) .073
Lower third 0.481 (0.384-0.602) b.001 0.665 (0.522-0.847) .001
Histological grade .014 .015
Well differentiated 1.00 1.00
Poorly differentiated 1.441 (1.077-1.929) 1.487 (1.081-2.046)
Anemia .006 .702
No 1.00 1.00
Yes 1.349 (1.092-1.667) 1.045 (0.837-1.311)
BMI (kg/m2) b.001
b18.5 1.00
≥18.5 to b25.0 0.817 (0.654-1.022) .077
≥25.0 0.593 (0.457-0.768) b.001
Serum albumin (g/l) b.001
b35 1.00
≥35 2.362 (1.767-3.156)
Preoperative weight loss b.001
b5% 1.00
≥5% to ≤10% 2.156 (1.722-2.698) b.001
N10% 2.184 (1.635-2.918) b.001
Nutrition status b.001 b.001
NR 1.00 1.00
ND 2.326 (1.876-2.885) 1.954 (1.552-2.460)
CEA b.001 .364
Normal 1.00 1.00
Elevated 1.665 (1.327-2.090) 1.114 (0.883-1.405)
TNM stage b.001 b.001
I 1.00 1.00
II 2.970 (1.602-5.507) b.001 2.429 (1.265-4.662) .008
III 12.573 (7.219-21.896) b.001 9.986 (5.537-18.008) b.001
Adjuvant chemotherapy .799
No 1.00
Yes 0.974 (0.794-1.194)
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histology group, and those with undifferentiated, signet ring cell, and
mucinous GC were categorized as the poorly differentiated histology
group [19].
Nutritional-Based Indices
The BMI was calculated as previously described (b18.5 kg/m2,
≥18.5 to b25.0 kg/m2, ≥25.0 kg/m2) [20]. Based on previous studies,
preoperative weight loss was divided into three groups: b5% weight
loss, 5% to 10% weight loss and N10% weight loss [15].
Patients were categorized into two groups: nutritionally replete
(NR) and ND. ND was defined as meeting one or more of the
following criteria: BMI b18.5 kg/m2, preoperative albumin b35 g/l,
or preoperative weight loss ≥5% of body weight [14,15].
Follow-Up
Patients were routinely followed up every 3 months during the first
2 years and every 6 months thereafter, including the laboratory
testing, dynamic abdominal computed tomography, and gastroscope
examination. The latest follow-up was June, 2015. Overall survival
(OS) was defined as the duration from the date of surgery until death
or last follow-up.
Statistical Analysis
Comparisons between groups were performed using the χ2 test for
categorical variables. Cumulative survival was estimated using theFigure 1. Overall survival based on nutritional status in patients wi
respectively.Kaplan-Meier method, and differences in survival rates between the
groups were assessed by the log-rank test. Variables that proved to be
significant (P b .05) in the univariate analysis and not significantly
associated with others were subsequently entered into a multivariate
Cox proportional hazards model. All statistical analyses were
performed using the SPSS statistical software package, version 19.0
(IBM Corporation, Armonk, NY). A two-sided P value b .05 was
considered significant.
Results
A total of 1026 GC patients were enrolled; 700 (68.2%) patients were
males, and 326 (31.8%) were females. The median age was 59 years,
with an age range from 19 to 89 years. A total of 177 patients were in
stage I, 257 were in stage II, and 592 were in stage III (Table 1).
Overall, 585 (57.0%) met the criteria for ND with one or more of the
following: BMI b18.5 kg/m2 (39.1%), preoperative albumin b35 g/l
(8.3%), and preoperative weight loss ≥5% (32.4%). One hundred
seventy patients (16.6%) had 2 ND factors, and 28 patients (2.7%)
had 3. The median follow-up period was 34 months (range 1-136).
During the follow-up period, 397 (38.7%) patients died, and 629
(61.3%) were alive at last follow-up.
OS at 5 years was 68.5% for NDpatients and 44.0% for NRpatients
(P b .001). The NR patients (96.8 months) had significantly longer
mean survival compared with ND patients (68.8 months) (P b .001).
The results of the univariate analysis were shown in Table 2. Because of
correlations among the BMI, serum albumin, preoperative weight loss,th stage I to III (A), stage I (B), stage II (C), and stage III (D) GC,
Figure 2. Overall survival based on nutritional status in female patients (A), male patients (B), patient b60 years old (C), and patients ≥ 60
years old (D), respectively.
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histological grade, anemia, nutrition status, CEA, and TNM stage) were
tested in a multivariate analysis. Multivariate analysis revealed that ND
was a strong predictor of OS (hazard ratio [HR]: 1.954; 95%
confidence interval (CI): 1.552-2.460; P b .001; Table 2). In
stage-stratified analysis, it was still independently associated with OS
in TNM stage II and III (P = .004 and P b .001, respectively).
However, its prognostic value was limited in TNM stage I (P = .146;
Figure 1). Furthermore, the prognostic significance of ND was still
maintained when stratified by age, sex, anemia, and adjuvant
chemotherapy (all Ps b .05; Figures 2 and 3). It should be noted that
ND was still associated with OS in patients with BMI ≥18.5 kg/m2,
preoperative weight loss b5% of body weight, or serum albumin ≥35 g/l,
respectively (all Ps b .001; Figure 4).
The relationship between nutrition status and clinicopathologic
characteristics in GC patients was shown in Table 3. Our study
showed that ND was associated with age ≥ 60 years (P = .030),
female patients (P b .001), larger tumor size (P b .001), higher
TNM stage (P b .001), the presence of preoperative anemia
(P b .001), and elevated CEA (P = .006).
Discussion
Because of the adverse impact on physical, psychological, and social
functions caused by cancer, malnutrition is common in patients with
cancer, especially gastrointestinal malignancies [21,22]. Estimated
prevalence rates can range from 9% in urological cancer and up to85% in pancreatic cancer [23]. Accumulating evidence has indicated
that malnutrition is associated with a series of clinical consequences,
including poor quality of life, decreased response to adjuvant
treatment, increased risk of chemotherapy-induced toxicity, and
poor outcome [24,25]. Therefore, early identification of malnutrition
is of vital importance among cancer patients, especially considering
that effective nutritional intervention may have an important role in
reducing postsurgical morbidity and mortality.
Over the past decades, a number of nutritional-based scores have
been proposed for determining the prognostic impact of nutritional
status in patients with various cancers. Recently, a prospective study
from Minami al, which used pretreatment BMI to evaluate
nutritional status, revealed that nutritional status might be a valuable
prognostic indicator in older GC patients [26]. A study from our
center provided concrete evidence that critical weight loss was a
significant and independent predictor of long-term survival in
nasopharyngeal carcinoma patients [27]. Lien et al reported that
preoperative low serum albumin level was an independent factor
correlated with prognosis and that postoperative adjuvant therapy
should be given to all GC patients with hypoalbuminemia
preoperatively [28]. Additionally, several composite scoring systems,
including the Nutritional Risk Index, Nutritional Risk Score, and
Geriatric Assessment, also failed to gain widespread consensus for
nutrition evaluation in gastrointestinal malignancies [9,29]. Thus, up
to now, no standardized method exists to identify patients at a high
nutritional risk preoperatively.
Figure 3. Overall survival based on nutritional status in nonanemic patients (B), anemic patients (A), patients without adjuvant
chemotherapy (C), and patients with adjuvant chemotherapy (D), respectively.
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objective and easily measurable criteria, has been increasingly getting
attention. ND, as measured by BMI, serum albumin, and
preoperative weight loss, has been validated as a strong predictor of
clinical outcome in urologic malignancies. One group found that ND
was associated with increased 90-day mortality and poor OS in
patients undergoing radical cystectomy for bladder cancer [14].
Another study reported that ND was a significant predictor of overall
mortality in patients undergoing nephrectomy for renal cell
carcinoma, independent of key clinicopathological factors [15]. In
fact, our conclusions were in line with the studies.
In the current study, we found that preoperative ND was
independently predictive of poor OS after curative resection for
GC, especially in TNM stage II and III GC. In subgroup analyses, its
prognostic significance was still maintained when stratified by age,
sex, anemia, and adjuvant chemotherapy. Furthermore, we found
that preoperative ND was associated with larger tumor size and higher
TNM stage. The observation was supported by previous studies
which indicated that poor nutritional status was significantly parallel
to tumor progression [30]. Tokunaga et al recently demonstrated in a
cohort of 556 patients with colorectal cancer undergoing surgery that
poor nutritional status was correlated with tumors invading muscular
or deeper layers, distant metastasis, tumor recurrence, and poor
survival [31].
Of note, ND was still associated with OS in patients with BMI
≥18.5 kg/m2, preoperative weight loss b5% of body weight, or serumalbumin ≥35 g/l, respectively. These data suggest, therefore, that ND
may identify more patients at high risk of recurrence or mortality
than the individual index. Obviously, ND, which includes all three
variables, was a more comprehensive and superior predictor to
evaluate nutritional status in GC. Furthermore, in stage-stratified
analysis, ND may have merit as a gauge of prognosis in patients with
GC at stage II and III. We speculated, in the context of stage I GC,
that nutritional status did not exert potent prognostic value. Given
that studies of Gregg and Morgan did not perform subgroup analysis
to support our conclusion, it is worthy of being further verified in
future studies [14,15].
In clinical practice, ND patients may need closer follow-up and
more aggressive adjuvant therapy. In addition, patients with ND may
benefit from nutritional support [32,33]. At present, although many
studies have reported the promising results of targeted nutritional
intervention in GC, no standardized method or strategy exists to
select appropriate patients [34,35]. Therefore, whether ND may aid
in the selection of patients with stage II to III GC likely to benefit
from nutritional intervention would be of considerable interest.
A potential limitation of the present study is that it was a retrospective
single-center study. However, our study is based on a large and
representative sample, which provides a valid base to evaluate the
prognostic significance of nutritional status. In addition, postoperative
treatment heterogeneity was inevitable because of the retrospective
design, which might have confounded the results. Finally, we lack
complete information on postoperative complications in our medical
Figure 4. Overall survival based on nutritional status in patients with BMI≥18.5 kg/m2 (A), preoperative weight loss b5%of bodyweight (B),
or serum albumin ≥35 g/l (C), respectively.
Table 3. The Relationships between Nutrition Status and Clinicopathological Characteristics
NR ND P Value
(n = 441) (n = 585)
Age (y) .030
b60 251 293
≥60 190 292
Sex b.001
Female 94 232
Male 347 353
Tumor size (cm) b.001
b5 294 289
≥5 147 296
Tumor location .103
Upper third 167 244
Middle third 80 122
Lower third 194 219
Histological grade .332
Well differentiated 81 94
Poorly differentiated 360 491
Anemia b.001
No 355 382
Yes 86 203
CEA .006
Normal 346 396
Elevated 77 137
TNM stage b.001
I 104 73
II 119 138
III 218 374
Adjuvant chemotherapy .690
No 172 221
Yes 269 364
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relationship between ND and postoperative complications.Conclusions
Our study showed that ND was a valuable independent predictor of
outcome in patients undergoing curative resection for GC, especially
in stage II to III GC. With our results in mind, we encourage
prospective randomized multicenter trials determining the clinical
utility of nutritional intervention in GC patients with ND.Competing Interests
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